You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Two Decades of HER2 Targeting: The Unfinished Revolution in Breast Cancer

  • Authors: Javier Cortes, MD, PhD; Erika Hamilton, MD; Shanu Modi, MD; Paolo Tarantino, MD
  • CME Released: 11/17/2022
  • Valid for credit through: 11/17/2023, 11:59 PM EST
Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US oncology specialists, pathologists, obstetricians and gynecologists, and any other healthcare professional involved in the management of patients with breast cancer.

The goal of this activity is for learners to be better able to highlight and demonstrate practical implications of recent data in HER2-expressing breast cancer.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Recent clinical trial evidence evaluating HER2-targeted therapies in breast cancer
    • Heterogeneity of HER2 clinicopathology
  • Demonstrate greater confidence in their ability to
    • Identify patients who may be candidates for emerging HER2-targeting treatments and/or suitable clinical trials


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


  • Javier Cortes, MD, PhD

    IBCC, International Breast Cancer Center
    Quiron Group, Barcelona
    Medica Scientia Innovation Research (MedSIR)
    Barcelona, Spain, and New Jersey, United States


    Javier Cortes, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Athenex; Bioasis Technologies, Inc.; BioInvent; Boehringer Ingelheim; Celgene; Cellestia; Clovis Oncology; Daiichi-Sankyo; Ellipses Pharma; Erytech; GEMoaB; Gilead Sciences; GlaxoSmithKline; HiberCell; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Roche; Seagen Inc.; Zymeworks
    Speaker or member of speakers bureau for: Celgene; Daiichi-Sankyo; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer, Inc.; Roche; Samsung Bioepis
    Research funding from: ARIAD Pharmaceuticals; AstraZeneca; Bayer Healthcare; Baxalta GmbH/Servier Affaires; Eisai; F. Hoffman-La Roche; Guardant Health; Merck Sharp & Dohme; Pfizer, Inc.; PIQUR Therapeutics; Puma Biotechnology; Roche
    Stock options from: Nektar Therapeutics


  • Erika Hamilton, MD

    Breast and Gynecologic Cancer Research Program
    Sarah Cannon Research Institute/Tennessee Oncology
    Nashville, Tennessee, United States


    Erika Hamilton, MD, has the following relevant financial relationships:
    Consultant or advisor for: Arcus Biosciences; Arvinas; AstraZeneca; Black Diamond Therapeutics; Boehringer Ingelheim; CytomX; Daiichi-Sankyo; Dantari; Deciphera Pharma.; Eisai; Greenwich LifeSciences; H3 Biomedicine; iTeos; Janssen; Lilly; Loxo; Merck; Mersana; Novartis; Orum Therapeutics; Pfizer, Inc.; Propella Therapeutics; Puma Biotechnology; Relay Therapeutics; Roche/Genentech; Seagen Inc.; Silverback Therapeutics
    Research funding from: AbbVie; Acerta Pharma; Accutar Biotechnology; ADC Therapeutics; Akesobio; Amgen; Aravive; ArQule; Artios; Arvinas; AstraZeneca; AtlasMedx; Black Diamond Therapeutics; Bliss BioPharmaceutical; Boehringer Ingelheim; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullen-Florentine; Curis; CytomX; Daiichi Sankyo; Dantari; Deciphera Pharma.; Duality Biologics; eFFECTOR Therapeutics; Ellipses Pharma; Elucida Oncology; EMD Serono; Fochon; Fujifilm; G1 Therapeutics; H3 Biomedicine; Harpoon Therapeutics; Hutchinson MediPharma; ImmunoGen; Immunomedics; Incyte; Infinity Pharma.; InvestisBio; Jacobio Pharma; Karyopharm; Leap Therapeutics; Lilly; Lycera; Mabspace Biosciences; MacroGenics; MedImmune; Merck; Mersana; Merus; Millennium Pharma.; Molecular Templates; Myriad Genetic Lab.; Novartis; NuCana; Olema; OncoMed; Onconova Therapeutics; ORIC Pharma.; Orinove; Pfizer, Inc.; PharmaMar; Pieris Pharma.; Pionyr ImmunoTherapeutics; Plexxikon; Radius Health; Regeneron; Relay Therapeutics; Repertoire Immune Medicines; RGENIX; Roche/Genentech; Seagen Inc.; Sermonix Pharma.; Shattuck Labs; Silverback Therapeutics; Stemcentrx; Sutro Biopharma; Syndax; Syros Pharma; Taiho Pharma; TapImmune; Tesaro; Tolmar; Torque Therapeutics; Treadwell Therapeutics; Verastem Oncology; Vincerx Pharma; Zenith Epigenetics; Zymeworks

  • Shanu Modi, MD

    Professor of Medicine
    Weill Cornell Medical College
    Section Head
    HER2 Breast Cancer Program
    Memorial Sloan Kettering Cancer Center
    New York, New York, United States


    Shanu Modi, MD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Daiichi-Sankyo; Genentech; MacroGenics; Seagen Inc.
    Research funding from: AstraZeneca; Daiichi-Sankyo; Genentech; Seagen Inc.

  • Paolo Tarantino, MD

    Clinical Research Fellow
    Dana-Farber Cancer Institute
    Harvard Medical School
    Boston, Massachusetts, United States


    Paolo Tarantino, MD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Daiichi-Sankyo
    Research funding from: AstraZeneca


  • Deborah Grainger, PhD

    Medical Education Director, WebMD Global, LLC


    Deborah Grainger, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Two Decades of HER2 Targeting: The Unfinished Revolution in Breast Cancer

Authors: Javier Cortes, MD, PhD; Erika Hamilton, MD; Shanu Modi, MD; Paolo Tarantino, MDFaculty and Disclosures

CME Released: 11/17/2022

Valid for credit through: 11/17/2023, 11:59 PM EST


Learning Feedback Questions

Please answer these questions to complement your learning experience.

  • Print